Stevanato Group (NYSE:STVN) Shares Down 7.8% - What's Next?

Shares of Stevanato Group S.p.A. (NYSE:STVN) fell by 7.8% in mid-day trading on Tuesday, reaching a low of €20.71 ($22.51) before finishing at €20.83 ($22.64). The trading volume for the day was approximately 76,087 shares, which is significantly lower—by 78%—than the average daily volume of 345,984 shares. The stock had closed at €22.60 ($24.57) on the previous trading day.

Wall Street Analysts Forecast Growth

The recent price drop has prompted several analysts to review their ratings and price targets for Stevanato Group. Bank of America recently increased its price target from $24.00 to $26.00 and maintained a "buy" rating on the shares. Meanwhile, Morgan Stanley reaffirmed an "equal weight" rating but reduced its target price from $24.00 to $23.00. UBS Group has also downgraded its price target from $24.00 to $23.50 while keeping a "neutral" stance on the stock.

In contrast, William Blair reiterated an "outperform" rating, highlighting the stock's potential. Wolfe Research has also begun its coverage with an "outperform" rating and a projected price of $28.00. In total, two analysts rate the stock as a hold, while six have given it a buy rating. According to MarketBeat, the consensus rating stands at "Moderate Buy" with an average target price of €27.75 ($30.16).

Stevanato Group Price Performance

Stevanato Group currently has a market capitalization of $6.42 billion, a price-to-earnings (PE) ratio of 45.11, and a price-to-earnings-growth (PEG) ratio of 7.18. Its stock beta is 0.60. The fifty-day simple moving average stands at €21.40, while the two-hundred day average is €20.57. The company has a current ratio of 1.81, a quick ratio of 1.21, and a debt-to-equity ratio of 0.22.

The company recently reported its quarterly earnings on March 6th, where it announced earnings per share of €0.20 ($0.22), aligning with analysts' estimates. Stevanato Group achieved a return on equity of 9.86% and a net margin of 10.47%. Its revenue for the quarter was €352.68 million, surpassing analyst expectations of €346.26 million. Analysts project that Stevanato Group will post an earnings per share (EPS) of 0.5 for the current fiscal year.

Institutional Trading of Stevanato Group

Recent activities by institutional investors have affected the stock’s trading dynamics. Van Berkom & Associates Inc. acquired a new stake valued at approximately $39,000. Similarly, Johnson Financial Group Inc. entered with a new position worth $41,000. Wells Fargo & Company MN increased its position substantially by 680.3%, now holding 3,246 shares valued at $71,000 after acquiring an additional 2,830 shares. PNC Financial Services Group Inc. also significantly grew its holdings by 1,457.6%, owning 5,654 shares valued at $123,000 after adding 5,291 shares.

Additionally, Tower Research Capital LLC TRC expanded its position by 202.8%, owning 7,413 shares worth $162,000 after acquiring 4,965 more shares during the last quarter.

Stevanato Group Company Profile

Stevanato Group S.p.A. specializes in providing integrated solutions for the biopharmaceutical and healthcare industries. It designs, manufactures, and distributes products and processes throughout Europe, the Middle East, Africa, North America, South America, and Asia Pacific. The company operates in two main segments: Biopharmaceutical and Diagnostic Solutions, as well as Engineering.

Should You Invest $1,000 in Stevanato Group Right Now?

Before considering an investment in Stevanato Group, it may be beneficial to examine other options. Current analysis indicates a "Moderate Buy" rating for Stevanato Group, yet top-rated analysts have identified other promising stocks not included in this list. This may present a better investment opportunity in the near term.

Stevanato, Stock, Earnings